LEADERS FREE 1 year follow-up proved 1 month of ultra-short DAPT following BioFreedom™
implant was significantly safer and more efficacious than the same strategy post BMS implant.
For more information on this landmark clinical trial of a previously understudied HBR population and key subgroups click here
Spotlight BioFreedom™PCI in High Bleeding Risk
(HBR) patients The challenge for PCI in HBR patients is balancing the ischemic vs the bleeding risk associated with long-term DAPT.
BioFreedom is the only active stent with CE mark for ultra-short 1 month DAPT in High bleeding Risk (HBR) patients, supported by clinical data from a double-blind randomized controlled trial.
BioFreedom and one month of DAPT followed by SAPT alone should be the treatment strategy of choice for HBR patient undergoing PCI.
BioMatrix NEOFLEX™BioMatrix NeoFlex™ is the latest addition to the BioMatrix family of drug-eluting stents (DES).™
It features an enhanced catheter delivery system with a lower entry profile than its predecessor, so improving pushability, trackability and crossability. BioMatrix NeoFlex retains the same unique combination of abluminal biodegradable polymer coating, Biolimus A9™ and flexible platform which have made the BioMatrix family of DES so popular.
First Patient enrolled in new US Pivotal BioFreedom™ Trial – “LEADERS FREE II”15 February 2017 - Biosensors International Group, Ltd. announced today the enrollment of the first patient in LEADERS FREE II.
Its new BioFreedom Pivotal Study, conducted under an Investigational Device Exemption (IDE), which will include sites in the United States, Canada, Denmark, France Germany, Italy, and the United Kingdom.